Maunsell Rebecca, Bellomo-Brandão Maria Angela
Medical Doctor and Associate Professor, Department of Otolaryngology, Universidade Estadual de Campinas (UNICAMP), Campinas (SP), Brazil.
Medical Doctor and Associate Professor, Department of Pediatrics, Universidade Estadual de Campinas (UNICAMP), Campinas (SP), Brazil.
Sao Paulo Med J. 2018 Jul-Aug;136(4):376-381. doi: 10.1590/1516-3180.2017.0031240317. Epub 2017 Sep 18.
Recurrent respiratory papillomatosis (RRP) is the most common laryngeal tumor. During childhood, it may present in extremely severe forms defined by the need for frequent surgical procedures to relieve respiratory distress and/or involvement of extralaryngeal sites such as lung involvement. Adjuvant therapies are indicated in these cases and interferon is one of the options. Pegylated interferon is more effective than conventional alpha interferon and, given its reported results in relation to treating hepatitis C over the past decade, we hypothesized that this might be more effective than conventional interferon also for treating respiratory papillomatosis. Use of a treatment strategy that eliminates the need for general anesthesia is particularly appealing, yet obtaining approval for use of medications that are not currently used for this purpose is challenging.
We report the case of a child with severe RRP that had been followed for the preceding six years, who was treated with pegylated interferon after failure of other adjuvant therapies. There was noticeable improvement in the frequency of surgical procedures, which was regarded very receptively, considering the child's history and previous response to other therapies.
Pegylated interferon may be a good option for diminishing the need for surgical intervention in severe cases of recurrent respiratory papillomatosis.
